{{위키데이터 속성 추적}}
{{Infobox drug
| Verifiedfields = changed
| verifiedrevid = 456485140
| image = Sodium oxybate.png
| alt = 
| caption =

<!-- Clinical data -->
| pronounce = 
| tradename = Xyrem, Alcover, Somsanit, others<ref name=brands/>
| Drugs.com = {{drugs.com|monograph|sodium-oxybate}}
| MedlinePlus = a605032
| licence_EU = yes
| DailyMedID = Sodium oxybate
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_category = 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = [[Oral administration|By mouth]]
| class = 
| ATCvet = 
| ATC_prefix = N07
| ATC_suffix = XX04
| ATC_supplemental =

<!-- Legal status -->
| legal_AU = S8
| legal_AU_comment = 
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment = 
| legal_CA = CDSA Schedule III/FDA Schedule G Part I
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = CD POM (Schedule 2)
| legal_UK_comment = 
| legal_US = Schedule I
| legal_US_comment = /&nbsp;Schedule III<ref name="Xyrem FDA label" />
| legal_EU = Rx-only
| legal_EU_comment =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment = 
| legal_status = Rx-only

<!-- Pharmacokinetic data -->
| bioavailability = 88%<ref name="Xyrem FDA label">{{웹 인용| title=Xyrem- sodium oxybate solution | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca | access-date=14 November 2020}}</ref>
| protein_bound = <1%<ref name="Xyrem FDA label"/>
| metabolism = 
| metabolites = 
| onset = 
| elimination_half-life = 0.5 to 1 hour.
| duration_of_action = 
| excretion = Almost entirely by biotransformation to [[carbon dioxide]], which is then eliminated by [[exhalation|expiration]]

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 502-85-2
| CAS_supplemental = 
| PubChem = 23663870
| IUPHAR_ligand = 4711
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01440
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9983
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7G33012534
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05866
| ChEBI_Ref = 
| ChEBI = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200682
| NIAID_ChemDB = 
| PDB_ligand = 
| synonyms = NSC-84223, WY-3478

<!-- Chemical and physical data -->
| IUPAC_name = sodium 4-hydroxybutanoate
| C=4 | H=7 | Na=1 | O=3
| SMILES = [Na+].[O-]C(=O)CCCO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1
| StdInChI_comment = 
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XYGBKMMCQDZQOZ-UHFFFAOYSA-M
| density = 
| density_notes = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| sol_units = 
| specific_rotation = 
}}

'''옥시베이트 나트륨'''({{llang|en|sodium oxybate}})은 [[기면증]] 증상, 즉 [[탈력발작|갑작스러운 근육 약화]] 및 [[과도한 주간 졸림증]]을 치료하는 데 사용되는 [[약물]]이다.<ref name="Xyrem FDA label" /><ref name="UKlabel">{{웹 인용|url=https://www.medicines.org.uk/emc/product/178|title=UK label Summary of Product Characteristics|date=8 September 2015|publisher=Electronic Medicines Compendium|access-date=14 April 2018}}</ref><ref>{{웹 인용|url=https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/xyrem-sodium-oxybate-information|title=Xyrem (sodium oxybate) Information.|date=25 January 2017|work=Center for Drug Evaluation and Research|publisher=U.S. Food and Drug Administration}}</ref> '''자이렘'''({{llang|en|Xyrem}})이라는 상품명으로 판매된다. 옥시베이트 나트륨은 때때로 [[프랑스]]와 [[이탈리아]]에서 정맥 주사로 투여되는 [[마취제]]로 사용된다.<ref name=WHO>{{웹 인용|title=Critical review of gamma-hydroxybutyric acid (GHB)|url=https://www.who.int/medicines/areas/quality_safety/4.1GHBcritical_review.pdf|date=2012}}</ref> 또한 이탈리아와 [[오스트리아]]에서 알코올 의존과 알코올 금단 증후군을 치료하기 위해 승인되고 사용된다.<ref name=AlcoverLabel>{{웹 인용|title=Alcover: Riassunto delle Caratteristiche del Prodotto|url=https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000223_027751_FI.pdf&retry=0&sys=m0b1l3 |date=31 March 2017|publisher=Agenzia Italiana del Farmaco}} [https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=027751 Index page]</ref>

== 같이 보기 ==
* [[기면증]]

== 각주 ==
{{각주}}

[[분류:GHB 수용체 작용제]]
[[분류:GABAB 수용체 작용제]]
[[분류:희귀약]]
[[분류:수면장애의 치료]]
[[분류:기면증]]
[[분류:유기산 나트륨염]]
[[분류:히스톤 탈아세틸화효소 저해제]]